Stockreport

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals, Inc.  (PMVP) 
PDF Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients wi [Read more]